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Abstract
Introduction: The ability of patients to finalise their affairs at the end of life is an often neglected aspect of quality of life
(QOL) measurement in palliative care effectiveness research despite compelling evidence of the high value patients place
on this domain.
Objective: This paper describes the preliminary development and evaluation of a new, single-item, end-of-life patient-
reported outcome measure (EOLPRO) designed to capture changes in the ability of patients to finalise their affairs at the
end of life.
Methods: Cognitive interviews with purposively sampled Australian palliative care patients (N= 9) were analysed
thematically to explore content validity. Simultaneously, secondary analysis of data from a randomised controlled trial
comparing ketamine and placebo for the management of cancer pain (N = 185) evaluated: construct validity; test-retest
reliability; and responsiveness.
Results: Preliminary findings suggest patients interpret the new measure consistently. The EOLPRO captures the ability to
complete physical tasks and finalise practical matters although it is unclear whether emotional tasks or resolution of
relationship issues are considered. Personal and financial affairs should be separated to allow for differences in ability for
these two types of affairs. The significant correlation between performance status and EOLPRO scores (r= 0.41, p,0.01,
n = 137) and expected relationships between EOLPRO and proximity to death and constipation demonstrated construct
validity. Pre- and post-treatment EOLPRO scores moderately agreed (n = 14, k= 0.52 [95% CI 0.19, 0.84]) supporting
reliability. The measure’s apparent lack of sensitivity to discriminate between treatment responders and non-responders
may be confounded.
Conclusion: Based on the preliminary findings, the EOLPRO should be separated into ‘personal’ and ‘financial’ affairs with
further testing suggested, particularly to verify coverage and responsiveness. Initial evaluation suggests that the single-item
EOLPRO is a useful addition to QOL outcome measurement in palliative care effectiveness research because common
palliative care specific QOL questionnaires do not include or explicitly capture this domain.
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Introduction
Despite compelling evidence that patients at the end of life and
their informal carers highly value the ability to finalise affairs at the
end of life, effectiveness studies rarely include or explicitly measure
this domain. It’s over a decade since Steinhauser et al. [1,2]
reported 94% (320/340) of seriously ill American veterans rated
having ‘financial affairs in order’ as very/important at the end of
life. The ability to ‘complete things and prepare for life’s end’ was
‘very/extremely important’ in 87% (349/434) of older Canadian
patients with advanced cancer and chronic end-stage medical
disease [3] and ‘preparation’ was highlighted as an important issue
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to measure at the end of life during in-depth interviews with ten
UK cancer patients [4]. Additionally, Patrick et al. [5] identified
‘preparation for death’ as a domain that should be included in a
‘quality of dying’ measurement tool based directly on feedback
from focus groups (n = 47), one-to-one interviews (n = 52) and a
review of the literature. Most recently, preparation for the end of
life was identified as a key component of a ‘good death’ by 23 UK
informants at different points along the dying trajectory [6]. Yet
this important quality of life (QOL) domain is not routinely
included in palliative care effectiveness research.
The European Organization for Research and Treatment of
Cancer quality of life palliative care (EORTC QLQ-C15-PAL)
[7], Functional Assessment of Chronic Illness Therapy - Palliative
Care (FACIT-Pal) [8], McGill Quality of Life [9] and Memorial
Symptom Assessment Scale questionnaires [10] do not include or
explicitly capture the ability of patients to finalise their affairs at
the end of life, yet these are amongst the most frequently used
multidimensional instruments for measuring QOL in palliative
care studies [11]. If outcome measures do not adequately highlight
such domains, service provision may fail to address complex issues
important to patients, like preparation for death, and focus solely
on managing physical symptoms [12]. Hence, a new, single-item,
end-of-life patient-reported outcome tool (EOLPRO) was devel-
oped to capture this domain whilst minimising any additional
patient burden due to multiple assessments [13].
Objective
The aims of this preliminary work were to develop and evaluate
the relevant psychometric properties of the new single-item tool:
content and construct validity; test-retest reliability for stability;
and feasibility.
Methods
The intention was to include the tool alongside several clinical
and patient-reported outcomes in the Australian Palliative Care
Clinical Studies Collaborative (PaCCSC) trials. PaCCSC is a
multi-site research collaborative evaluating the net benefit of
different palliative care pharmacological interventions in phase III
studies [14]. Medications being studied, such as ketamine, could
affect patients’ ability to finalise their affairs in preparation for
death due to adverse effects, including sedation or confusion [15].
The initial PaCCSC studies administered the FACIT-Pal and
EORTC QLQ-C15-PAL, neither of which includes the ability to
finalise affairs. Consequently, a single-item scale measuring the
ability of patients to finalise their affairs in preparation for death
was sought to add to the other outcome measures, minimising
additional respondent burden and promoting feasibility [16]. The
most recent systematic review examining end-of-life measures [17]
was used to identify single-item scales. Two measurement tools,
the Palliative Care Outcome scale (POS) [18] and the Missoula
VITAS quality of life index (MVQOLI) [19] met these criteria.
However, the attribute-specific question in the MVQOLI has not
been tested as an individual item and members of the PaCCSC
Scientific Committee thought the item lacked clarity, whereas the
POS question concerns specific rather than general practical
matters and the measurement time frame is limited to three days
(see Figure S1). Consequently, based on the MVQOLI and POS
items, a new EOLPRO was constructed (see Table 1).
It is important to ensure that the new tool is psychometrically
sound [20]. Consequently scale reliability and validity need to be
assessed commensurate with the requirements of a single-item
scale. The instrument should measure the concept it was designed
to capture (content validity); have theoretically meaningful
relationships with other measures (construct validity); and repro-
duce the same results in similar circumstances (test-retest reliability
for stability) [21,22]. Additionally, the measurement tool should
pick up differences in actual observed outcomes when present
(responsiveness) [20,23] and should be appropriately designed for
the target population (feasibility) [21].
The EOLPRO was evaluated in two ways: (1) investigation of
the content validity and feasibility through cognitive interviews;
and (2) psychometric evaluation using a subset of data from a
randomised controlled trial (RCT) comparing subcutaneous
ketamine and placebo for the management of cancer pain
(Australian New Zealand Clinical Trials Registry
12607000501448) [24].
1. Content Validity and Feasibility
A qualitative study was conducted to investigate whether
respondents interpret the measure as intended and key aspects
of the domain of interest could be adequately represented and
captured by the single-item scale (feasibility).
Settings and participants. Participants were recruited from
patients under the care of the palliative care team at the Royal
Adelaide Hospital (RAH), South Australia. Brief, semi-structured,
face to face, cognitive interviews were conducted with participants
to explore palliative care patients’ interpretation of the statement ‘I
am able to manage my personal and financial affairs as I would
wish’ and the associated response categories [25]. Participants
were purposively sampled on age, gender, diagnosis (cancer, heart
failure, chronic obstructive pulmonary disease (COPD), AIDS),
education level and performance status, reflecting characteristics
of the target population and covering a wide range of cases to
detect variation [26]. The absolute sample size was determined by
data saturation i.e., until new, dominant issues no longer emerged
from the interviews [27]. Patients meeting the following criteria
were eligible for the study: $18 years of age; advanced cancer or
non-cancer life-limiting illness; knowledge of diagnosis and
prognosis; physically and mentally competent; English-speaking;
able to read the study questionnaire; cognitively intact, defined
according to a Mini-Mental State Examination score [28] $19;
and physically able to participate, defined as Australian-modified
Karnofsky Performance Status (AKPS) [29] score $40. Ethical
approval for the study (including the consent procedure) was
gained through the Flinders University and Southern Adelaide
Health Services Social and Behavioural Research Ethics Com-
mittee and the RAH Research Ethics Committee.
Data collection. Written consent was obtained from partic-
ipants. The signed consent form was inserted in the clinical file and
a copy was given to the participant. Consented participants
Table 1. The end-of-life patient-reported outcome measure.
Not at all A little bit Some-what Quite a bit Very much
I am able to manage my personal and financial affairs as I would wish……… 0 1 2 3 4
doi:10.1371/journal.pone.0094316.t001
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meeting the eligibility criteria took part in an interview with the
lead author (NM) in their location of choice. First, the EORTC
QLQ-C15-PAL questionnaire [7] was administered and complet-
ed individually, followed by the EOLPRO, reflecting question-
naire ordering in the PaCCSC studies. The EORTC QLQ-C15-
PAL is an abbreviated 15-item version of the most widely used and
validated cancer-specific HRQOL measure (the EORTC QLQ-
C30 questionnaire), specifically developed for palliative care [7].
The questionnaire consists of 14 items, each with four possible
responses (not at all, a little, quite a bit, and very much) and a
QOL rating scale with seven categories ranging from 0 (very poor)
to 7 (excellent). The participant’s interpretation of the EOLPRO
was then explored and digitally recorded using scripted and
spontaneous verbal probing (Figure 1). In verbal probing the
interviewer asks specific questions about how the respondent
answered a question with follow up probing if required. Verbal
probing is thought to pose less of a burden as it requires less
comprehension of thinking processes [30], is better at detecting
ambiguity, and facilitates elicitation of specific types of information
[26]. Consequently, brief, face to face cognitive interviews with
verbal probing were chosen as the optimal approach for data
collection for this frail population [26].
Recordings were transcribed verbatim and checked for accura-
cy. Willing participants underwent a second interview approxi-
mately five months later to comment on the accuracy of the
analysis as a means of actively engaging the participants in the
research process and verifying the results [31].
Data analysis. Demographic and clinical data were analysed
using descriptive analysis. The transcribed interviews were
analysed in QSR International’s NVivo version 8, 2008 (Don-
caster, Australia) using constant comparative thematic analysis
[32,33]. Interview transcripts were iteratively reviewed and coded
using open coding (data analysed using line-by-line coding), axial
coding (data categorised and linked), and selective coding
(overarching themes established and linked together) [32,33].
Three of the interview transcripts were coded independently by a
second researcher (KB) and the analysis was verified with
members of the multi-disciplinary Palliative and Supportive
Services Research Group at Flinders University [31]. Feedback
interviews were analysed separately. The thematic analysis, and
member and respondent verification informed: (i) the evaluation of
the content validity of the EOLPRO; and (ii) the feasibility of
measuring the ability to finalise affairs at the end of life with a
single-item scale.
2. Psychometric Evaluation
Data from the multi-site, double-blind, parallel arm, dose
titrated, Phase III PaCCSC RCT evaluating the net benefit of
subcutaneous ketamine relative to placebo for the management of
cancer pain (hereon in termed the ‘ketamine trial’) [24] were used
to evaluate the psychometric properties of the EOLPRO.
Figure 1. Scripted probes for the cognitive interview.
doi:10.1371/journal.pone.0094316.g001
Table 2. Key eligibility criteria in the ketamine trial [24].
Inclusion criteria Exclusion criteria
Age .18 years Previous ketamine use in the last six months
Pain related to cancer or its treatment Unstable pain, or undergoing active treatment to reduce pain (surgery,
chemotherapy, radiotherapy)
Moderate to severe pain Medical history places patient at risk of known adverse reactions
Patients with either primarily nociceptivea or predominantly neuropathic painb
treated appropriately
Recent monoamine oxidase inhibitors
Stable background opioid dose Previous recreational drug history
Stable co-analgesics during the study period
aLeeds Assessment of Neuropathic Symptoms and Signs score (LANSS) ,12;
bLANSS score .12.
doi:10.1371/journal.pone.0094316.t002
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Settings and participants. The total sample consisted of
185 inpatients with uncontrolled cancer pain despite aggressive use
of standard analgesics [24]. Participants were randomised to
titrated subcutaneous ketamine infusion or placebo for up to five
days. The key eligibility criteria for the ketamine trial are
summarised in Table 2.
Data collection. Measures in the ketamine trial relevant for
the psychometric analysis included: the AKPS [29]; the Brief Pain
Inventory scale (BPI) [34]; and the EORTC QLQ-C15-PAL
questionnaire [7]. The AKPS is a validated measurement tool that
assesses patient functioning and performance, and broadly
correlates with prognosis in patients with cancer and AIDS [29].
The AKPS is an ordered, categorical scale with 11 levels and
scores between 0 and 100; 0 represents death and 100 indicates
normality, with no symptomatic complaints and no evidence of
disease. The BPI is a numeric rating scale (0–10) which has been
validated in advanced cancer and chronic pain [35–38]. The scale
was used to measure the average pain severity where 0 represents
‘no pain’ and 10 indicates ‘pain as bad as you can imagine’
[39,40].
Data analysis. Descriptive statistics were reported for
demographic data and the measures listed above. Complete case
analyses were conducted. All analyses were performed in PASW
for Windows version 18 (SPSS Inc., Chicago, IL).
Construct validation. Construct validity was assessed by
investigating hypothesised relationships between the EOLPRO
scores and scores from the relevant, established scales in the
ketamine trial using Spearman’s rank correlations [19]. Baseline
EOLPRO scores were expected, at best, to moderately correlate (+)
with baseline AKPS because the cognitive interviews suggested that
a participant’s ability tomanage their affairs is strongly influenced by
their degree of independence, which is affected by physical and
cognitive functioning. Lower levels of physical functioning were
expected to reduce the ability to manage one’s affairs [41–44].
Baseline EOLPRO scores were hypothesises to weakly correlate (2)
withBPI scores as greater levels of pain inhibit physical and cognitive
functioning which indirectly influences the ability to manage one’s
affairs [13,40,44,45]. It was anticipated that baseline EOLPRO
scores would moderately correlate (+) with proximity to death as the
ability to manage one’s affairs at the end of life diminishes with
declining physical and cognitive functioning as death approaches
[46–48]. Finally, little or no correlation was anticipated between
baseline EOLPRO scores and participants’ degree of constipation
measured using the EORTCQLQ-C15-PAL question, ‘during the
last week have you been constipated?’ (question 10) as this question
measures an unrelated construct. Correlations of less than 0.3 were
considered relatively weak, 0.30–0.50 moderate and .0.70 strong
[16,49,50].
Test-retest reliability. Test-retest reliability for stability
indicates whether a measurement tool produces consistent results
when a condition is stable [51]. Establishing a ‘stable’ phase in a
palliative care population is difficult given the different patterns of
symptoms experienced by different patients, the expected contin-
ual functional decline over time and somewhat heterogenous
trajectories before death [48]. Consequently, test-retest reliability
was evaluated in a subgroup of the ketamine study participants,
those with stable AKPS and BPI scores pre- and post-treatment.
These participants were expected to have a stable clinical
condition and stable ability to manage their affairs. Two
definitions of stable scores were applied: equal pre- and post-
treatment AKPS and pain scores; and equal pre- and post-
treatment AKPS scores and post-treatment pain scores within plus
or minus one category of the baseline pain score (as the minimal
clinically important different pain score in the ketamine RCT was
plus or minus two categories). Test-retest reliability was deter-
mined using the weighted Kappa Measure of Agreement which
evaluates the degree of agreement between ordinal measures
[51,52]. A weighted kappa less than 0.2 was considered to indicate
slight agreement, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
substantial and 0.81–1.00 almost perfect agreement [53]. Pre- and
post-treatment EOLPRO scores were hypothesised to moderately,
rather than substantially, agree because outcome measurements
were taken five days apart and changes in other deteriorating
symptoms such as fatigue, or treatment side effects, could affect the
ability to manage affairs at the end of life in this subgroup of
participants with stable pain [54], reducing test-retest agreement.
Note the outcome measurement time points were pre-determined
by the ketamine study protocol.
Responsiveness. Responsiveness of the EOLPRO was
evaluated by investigating whether the measure discriminated
between participants in the ketamine study who did and did not
respond to treatment using the Chi-square test for independence
[55]. Response was defined as: BPI average pain score at the start
of Day 6 (i.e., after 5 days of ketamine/placebo) reduced by $2
points from baseline, in the absence of any increase in baseline
opioid dose, and who had #4 breakthrough opioid doses in the
last 24 hours; or a participant who withdrew before day 6, where
the reason for withdrawal was unrelated to treatment and where
Table 3. Qualitative study participant characteristics.
Characteristic Total number (N=9)
Demographics
Age in years, mean (range) 69 (47–88)
Gender, M/F 3/6
English is the usual language spoken at home, n 9
Primary caregiver identified, n 7
Highest education level achieved, n
Up to year 9 2
Years 10–12 4
Completed university or TAFE 2
Postgraduate 1
Clinical data
Main life limiting illness, n
Advanced cancer 4
Motor Neurone Disease 3
Heart Failure 1
COPD 1
Time since diagnosis (months), median (IQR) 12 (11)
min-max 1–120
MMSE score, mean (range) 28 (28–30)
AKPS score, n
80 2
70 1
60 2
50 3
40 1
AKPS = Australian-modified Karnofsky Performance Status; COPD = chronic
obstructive pulmonary disease; F = female; IQR = inter-quartile range; M =
male; MMSE = Mini-Mental State Examination; SD = standard deviation; TAFE
= Technical and Further Education.
doi:10.1371/journal.pone.0094316.t003
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Figure 2. Links between key themes identified from the cognitive interviews.
doi:10.1371/journal.pone.0094316.g002
Table 4. Ketamine sample baseline characteristics.
Characteristic Number of cases (N=185)
Age (years), mean (SD) 63.6 (11.9) 182
Gender, male (%) 103 (56.6) 182
Site of cancer diagnosis (n = 183), n (%)
Lung 40 (21.9)
Prostate 24 (13.1)
Colorectal 22 (12.0)
Breast 17 (9.3)
Gynaecologic 11 (6.0)
Pancreas 10 (5.5)
Bone/soft tissue 7 (3.8)
Other 52 (28.4)
EOLPRO, median (IQR)1 3 (2) 1372
AKPS, median (IQR)1 60 (10) 182
EORTC QLQ-C15-PAL Question 10, median (IQR)1 2 (2) 160
BPI, mean (SD)3 5.3 (1.4) 181
1the median and interquartile range are reported given the ordinal nature of the data;
2the EOLPRO was introduced 5 months after study initiation;
3the distribution of the BPI was approximately normal, hence the mean and standard deviation are reported; AKPS = Australian-modified Karnofsky Performance Status;
BPI = Brief Pain Inventory Scale; EOLPRO = end of life patient reported outcome; IQR = interquartile range; SD = standard deviation.
doi:10.1371/journal.pone.0094316.t004
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the patient for whom a pain score at the start of day 6 was not
available, but whose last recorded pain score was reduced $2
points from baseline and who had #4 breakthrough opioid doses
in the last 24 hours [24]. Participants who responded to treatment
were expected to experience an increased ability to manage their
affairs compared with non-responders as pain levels influence
levels of functioning [40]. Consequently, post-treatment EOLPRO
scores were hypothesised to differ between responders and non-
responders.
Results of the statistical tests were considered significant when
the probability of making a type I error was less than 0.8%
adjusting for multiple testing using the conservative Bonferroni
method [56,57].
Results
1. Content Validation and Feasibility
Seventeen palliative care patients were invited to participate
and nine patients consented. Reasons for not participating
included: not stated (n = 3); not meeting the inclusion criteria
(n = 2); lack of energy (n = 1); aversion to questionnaires (n = 1);
and admission to hospice for terminal care prior to participation
(n = 1). New, dominant issues no longer emerged by the ninth
interview, i.e. data saturation was reached. Interviews lasted 6–23
minutes. Participant characteristics are summarised in Table 3.
There was a great degree of commonality between the
participants’ interpretation of the phrase, ‘I am able to manage
my personal and financial affairs as I would wish’; only one
participant thought the question itself unclear. Participants wanted
to manage their personal and financial affairs, and managing
affairs helped them feel valued.
Participants considered financial and practical matters (money,
investments funeral arrangements, wills), personal care (hygiene,
socialising, shopping) and preparation for death (handing over
tasks to other family members, advance directives, saying good-
byes) when choosing a response category (see Figure 2). No-one
explicitly discussed emotional tasks or resolving relationship issues.
The ability to complete activities without assistance from others
ranked a higher EOLPRO score than those requiring assistance.
Devices enabling interviewees to physically conduct activities, such
as using a wheelchair for mobility or the computer to pay bills
aided independence, promoting the ability to manage. Indepen-
dence was strongly linked to cognitive and physical functioning.
Cognitive abilities were most often tied to the ability to manage
financial affairs whilst physical functioning was predominantly
linked with personal affairs, with some overlap. Participants
expected their physical and mental functioning would decline over
time, reducing their ability to manage and participants wished to
prepare for death before functional deterioration prevented them
from completing activities such as arranging the funeral.
Most participants thought the categories were appropriate
although two interviewees thought ‘very much’ meant that an
individual could not manage their affairs. Nearly all of the
participants suggested that the question should be split into two:
one question about personal affairs and one about financial affairs.
None of the participants (n = 4) reported inaccuracies in the
thematic analysis during the follow-up interview. Three members
of the research group verified ‘managing’, ‘personal and financial
affairs’, and ‘expectation of abilities’ as major themes.
Table 5. Proportion of missing values for key variables in the ketamine sample data.
Variable Missing Available
Baseline n (%) Follow up n (%) Baseline n (%) Follow up n (%)
EOLPRO 48 (25.9) 81 (43.8) 137 (74.1) 104 (56.2)
EORTC QLQ-C15-PAL QOL 32 (17.3) 73 (39.5) 153 (82.7) 112 (60.5)
EORTC QLQ-C15-PAL Qu 10 25 (13.5) 71 (38.4) 160 (86.5) 114 (61.6)
AKPS 3 (1.6) 8 (4.3) 182 (98.4) 177 (95.7)
BPI score 4 (2.2) 13 (7.0) 181 (97.8) 172 (93.0)
AKPS = Australian-modified Karnofsky Performance Status; BPI = Brief Pain Inventory; EOLPRO = end of life patient reported outcome; MMSE = Mini-Mental State
Examination; QOL = quality of life.
doi:10.1371/journal.pone.0094316.t005
Table 6. Summary of the correlations between EOLPRO scores and other established scales and clinical measures.
Measure Spearman’s correlation coefficient (95% CI) Effect size p-value1
Convergent validity
AKPS (n = 137) 0.41 (0.26, 0.54) moderate ,0.01*
BPI (n = 137) 0.10 (20.08, 0.26) very weak 0.25
Proximity to death (n = 28) 0.30 (20.09, 0.59) moderate 0.13
Divergent validity
EORTC QLQ-C15-PAL Question 10 (n = 127) 0.02 (20.15, 0.19) negligible 0.85
1correlations were considered significant when the probability of making a type I error was less than 0.8% to allow for multiple testing;
*statistically significant result; AKPS = Australian-modified Karnofsky Performance Status; BPI = Brief Pain Inventory; CI = bootstrap BCa confidence intervals.
doi:10.1371/journal.pone.0094316.t006
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2. Psychometric Evaluation
The intention-to-treat study sample comprised 185 patients;
four randomised participants withdrew before commencement of
the study drug. Ketamine sample baseline characteristics are
shown in Table 4. Demographically, the study population was
fairly typical of the Australian cancer population [58].
Table 5 shows the proportion of missing values for the relevant,
established scales in the sample data. The QOL measures had the
greatest proportion of missing values.
Construct validation. Data depicting construct validity are
summarised in Table 6. As anticipated, there was a moderate,
positive, statistically significant correlation between baseline AKPS
and EOLPRO scores (r=0.41, p,0.01), with greater performance
status associated with an increased ability to manage affairs.
Correlations between baseline EOLPRO scores and proximity to
death (r=0.30, p = 0.13) were moderate, positive and non-
significant. In other words, longer survival was associated with
an increased ability to manage affairs, as expected. Little
correlation was found between baseline average pain and
EOLPRO scores (r=0.10, p = 0.25). Furthermore, this relation-
ship was opposite to the anticipated direction. There was a
negligible, non-significant correlation between baseline levels of
constipation and EOLPRO scores (r=0.02, p= 0.85), as antici-
pated, supporting divergent validity.
Test-retest reliability for stability. The weighted Kappa
Measure of Agreement suggested moderate agreement between
pre- and post-treatment EOLPRO scores (stable definition 1,
n = 14, k=0.52 (95% CI 0.19, 0.84) and stable definition 2,
n = 32, k=0.48 (95% CI 0.25, 0.72) [53]. The 95% CIs were
calculated using the web-based kappa with linear weighting
calculator found at http://vassarstats.net/kappa.html.
Responsiveness. A Chi-square test for independence indi-
cated no statistically significant difference in post-treatment
EOLPRO scores between responders and non-responders
(x2= 0.43, unadjusted p= 0.98; see Table 7). Furthermore, the
Cramer’s V, suggested there was little, if any, association between
responder status and post-treatment EOLPRO score (V= 0.06)
[59].
Discussion
The EOLPRO was developed to be used in addition to other
palliative care QOL instruments to capture changes in the ability
to manage one’s affairs in preparation for death for health services
research. Very few QOL questionnaires consider constructs
capturing this patient-valued domain. Within this context, the
preliminary findings for content and construct validity, test-retest
reliability, responsiveness and feasibility presented in this study are
encouraging.
The thematic analysis, and member and respondent verification
suggest that the EOLPRO adequately captures patients’ ability to
complete physical tasks and finalise practical matters in prepara-
tion for death. Qualitative palliative care studies evaluating factors
that are important to measure in the last weeks of life collectively
suggest that ‘preparation’ should include: financial matters; funeral
arrangements; writing a will; resolution of conflicts; emotional
matters; completion of goodbyes; and legal arrangements
[1,2,4,5,17,18,60–63]. Whilst virtually all of these items were
mentioned during the cognitive interviews it is unclear whether the
EOLPRO provokes thoughts of emotional and unresolved
relationship issues or closure before death. Participants may have
been unwilling to consider such painful aspects or to discuss
personal and sensitive aspects of preparation for death. Such
matters may not be relevant for individuals. Alternatively, the term
‘personal affairs’ may not resonate with participants who have not
yet needed help with these aspects. Although the interview
questions may have highlighted the ‘personal’ versus ‘financial’
issue (see questions 3 and 4, Figure 1), following the findings of the
qualitative interviews, future iterations of the EOLPRO should
split the statement into ‘personal affairs’ and ‘financial affairs’ to
allow coverage of both aspects and improve content validity.
Although the sample size was relatively small and the interviews
were short (median length 10 minutes) data saturation was
reached by the ninth interview as new, dominant themes no longer
emerged. For example, new facets of ‘preparation’ were no longer
emerging by the ninth interview. Consequently it was considered
unethical to continue interviewing more participants. The semi-
structured cognitive interviews were kept deliberately brief due to
the frail status of the population and focused on participants’
interpretation of the EOLPRO, particularly what activities were
considered when thinking about personal and financial affairs and
what ‘ability to manage’ meant. Also note the interview length
does not include administration of the QOL questionnaires. There
is evidence to suggest that six interviews with purposively sampled
participants are sufficient to identify dominant issues [64].
Although one interview lasted only six minutes interpretation of
the EOLPRO was adequately described with examples cited of
personal and financial affairs, differences in the response categories
outlined and consideration of response category detailed. This
participant was an inpatient with an AKPS score of 50 (requires
considerable assistance and frequent medical care).
The EOLPRO scores were moderately correlated with the
AKPS scores providing support for convergent validity given the
highly statistically significant and expected relationship between
physical functioning and the ability to manage affairs at the end of
life. Additionally, divergent validity is supported by the anticipated
negligible relationship between baseline levels of constipation and
EOLPRO scores.
The EOLPRO scores were only weakly correlated with pain
scores, possibly due to the exclusion of patients with mild pain
from the ketamine RCT [24]. Furthermore, the direction of the
relationship between EOLPRO and pain scores was opposite to
the anticipated direction. These unexpected results may be due to
gender differences in pain scores. Although there was a negligible,
Table 7. Post-treatment EOLPRO scores and responder status cross tabulation.
Post-treatment EOLPRO scores n (%)
0: not at all 1: a little bit 2: somewhat 3: quite a bit 4: very much Total
Responder 3 (8.6) 4 (11.4) 8 (22.9) 7 (20.0) 13 (37.1) 35
Non-responder 8 (11.6) 6 (8.7) 15 (21.7) 15 (21.7) 25 (36.2) 69
Total 11 (10.6) 10 (9.6) 23 (22.1) 22 (21.2) 38 (36.5) 104
doi:10.1371/journal.pone.0094316.t007
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negative, non-significant correlation between scores for males
(r=20.02, p= 0.87, n= 75), there was a weak, positive, statisti-
cally significant correlation for female participants (r=0.27,
p = 0.04, n = 62). Women ‘catastrophize’ pain more commonly
than men [65], perhaps spurring end of life preparation.
Alternatively, these results may be due to gender differences in
perceptions of financial and personal matters, particularly as
nearly all participants in the qualitative study suggested the
EOLPRO should be split into one question about personal affairs
and one about financial affairs. More work is required to
understand the reported difference between genders and patients’
abilities to manage their affairs at the end of life.
When assessing stability, the results suggest, at best, a moderate
agreement between the test-retest EOLPRO scores in participants
with stable AKPS and average pain scores. Stable AKPS and
average BPI scores were assumed to reflect clinical stability and
therefore a stable ability to manage affairs. However, it cannot be
excluded that pre- and post-treatment EOLPRO measures were
captured under heterogenous conditions due to changes in other
clinical symptoms, such as fatigue or breathlessness affecting the
ability to manage affairs at the end of life [55,66], leading to less
than perfect test-retest agreement.
Response status may not have been significantly associated with
EOLPRO scores as pain could be too indirectly related to the
construct ‘‘preparation for death’’, particularly given the very
weak relationship between baseline EOLPRO and average BPI
scores. Moreover, an interaction effect between gender and pain
may be confounding the comparison. Further testing is required
using more robust measures to support the responsiveness of the
EOLPRO.
The new scale is designed to be used alongside multiple clinical
and patient-reported outcomes in palliative care RCTs. Conse-
quently, a single-item scale was chosen to capture the ability to
manage affairs at the end of life in this frail population to minimise
any additional administration and respondent burden associated
with the new measure. Single-item scales tend to be simple and
concise, easily interpreted, and quickly completed, whereas multi-
item scales can be time consuming, difficult to interpret and
burdensome [67,68]. However, it may have been overly ambitious
to hope one scale could cover all the key attributes of preparation
for death [68]. Even though multi-item scales may improve
coverage, consistency, stability, precision, reliability and respon-
siveness [67,69] the practicality and feasibility [16] of the scale
were considered important arguments against pursuing higher
levels of psychometric acceptability typical in the development of
rating scales in other clinical areas.
Approximately 47% of the baseline EOLPRO responses
clustered in the ‘very much’ category suggesting nearly half of
the sample could manage their affairs. A visual analogue scale
(VAS) rather than a five category ordinal scale may have better
captured variability in the domain, although empirical findings
comparing the relative benefits of these scales are contradictory,
and advantages are likely context specific [69,70]. For example, as
respondents get older and cognitive impairment increases, more
errors have been reported when using the VAS compared with
ordinal scales to measure pain intensity [71]. Categories in an
ordinal scale may be easier for respondents to understand than a
VAS anchored with extreme values [52,71–73].
Limitations
The qualitative and quantitative components of this study were
conducted simultaneously as this preliminary work aimed to
evaluate whether the single-item EOLPRO was fit for purpose
rather than to develop the items for the scale. Conducting
cognitive interviews before administration of the single-item scale
could have usefully informed refinement of the measure to allow
for differences in ability to finalise ‘personal’ or ‘financial’ affairs.
As with many longitudinal studies involving palliative care
populations [74,75] there is a sizeable proportion of missing values
in the ketamine sample data. Palliative care patients’ health
declines over time, fatigue may be more of an issue compared with
other study populations, and outcome measurement can become
burdensome, more readily leading to non-response or drop out.
The missing values reduce the power to reject a false null
hypothesis of no relationship between the chosen measures due to
the smaller sample size from complete case analysis [76],
particularly for weaker relationships. There was a higher
proportion of missing data for the EOLPRO compared with the
other QOL measures possibly due to outcome measure ordering
as the EOLPRO was administered after the EORTC QLQ-C15-
PAL and clinical measures. In a palliative care population, earlier
administered outcome measures may be more likely to be
completed given outcome measurement burden in this frail
population. This finding further supports keeping measurement
as simple as possible in a palliative care population.
The ketamine study population comprised solely of inpatients
with chronic cancer pain who self-administered the EOLPRO
after the EORTC QLQ-C15-PAL questionnaire. Validity, reli-
ability and responsiveness of the EOLPRO can only be
ascertained for similar administration conditions and patient
populations.
Conclusion
In conclusion, the EOLPRO is a single-item, end-of-life patient-
reported outcome measure that was developed to capture changes
in the ability of patients to finalise their affairs at the end of life
whilst minimising any additional patient burden due to multiple
assessments. The preliminary findings suggest the EOLPRO
should be separated into ‘personal’ and ‘financial’ affairs with
further testing suggested, particularly to verify coverage and
responsiveness. Furthermore, implications of gender differences in
patients’ abilities to manage their affairs and pain perception
warrant additional investigation. Currently, common palliative
care QOL questionnaires do not include or explicitly capture the
ability of patients to finalise their affairs at the end of life despite
compelling evidence that patients and their informal carers highly
value this domain. Consequently, despite limited coverage, until
an amended version of the single-item scale has been developed
and tested, use of the single-item EOLPRO in addition to QOL
outcome measurement is suggested as valuable in palliative care
effectiveness research.
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